ArticleBreast cancer research : BCR2026
CLIC3 is upregulated across all subtypes of breast cancer and plays a key role in cell migration, invasion and growth in soft agar.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWomen with metastatic breast cancer have a disheartening 5-year survival rate of only 28%. CREB3L1 (cAMP responsive element binding protein 3 like 1) is a transcription factor and tumor suppressor which is downregulated in ~ 30% of human breast cancers, with higher frequencies in more advanced metastatic breast tumors.
methodsTo identify new targets contributing to metastatic properties, we carried out a differential gene expression analysis between highly metastatic breast cancer cells with low CREB3L1 and the corresponding lines expressing HA-CREB3L1. This analysis was carried out across three different subtypes of breast cancer cells (T47D, HCC1954 and HCC1806; all CREB3L1-low). Key signaling pathways and cell functions most impacted by CREB3L1 expression were identified using a bioinformatics analysis. Specific genes consistently upregulated in the metastatic cells were knocked down to assess their impact on cell migration, cell invasion, growth in soft agar across in multiple breast cancer lines. The effect of knocking down the top metastatic gene identified in this study was further tested using in vivo mouse model of primary breast tumor growth in the mammary fat pad, and metastatic colonization of the lung.
resultsBreast cancer cells with low CREB3L1 expression showed upregulation of metastasis and integrin signaling pathways and enhanced cell movement, migration, invasion functions, consistent with its known role as a tumor suppressor. CLIC3 (chloride intracellular channel 3), a protein with roles in integrin recycling, cell migration and invasion, was found to be consistently upregulated in CREB3L1-low cells and in all subtypes of breast tumors. Increased CLIC3 expression was associated with poor patient survival. Knockdown of CLIC3 in several cell lines reduced cell migration, invasion and anchorage-independent growth in soft agar, effects that could be rescued by co-transfection of an shRNA-insensitive CLIC3 plasmid. CLIC3 knockdown also decreased tumor growth and blocked metastases in a mouse xenograft model of breast cancer.
conclusionsThese results suggest that CLIC3 has a key role in promoting cell migration, invasion and growth in soft agar, and CLIC3 inhibitors may be a viable treatment option for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.